Dr. Daixing Zhou

Dr. Daixing Zhou co-founded Berry Genomics in 2010, and since then has served as the CEO of the company. He and his colleagues at Berry Genomics pioneered the non-invasive prenatal testing (NIPT) and other next-generation sequencing based medical applications in China. He has taken Berry Genomics from a start-up company to the publicly traded leading IVD company in China.

Prior to founding Berry Genomics, Dr. Zhou spent many years in developing and commercializing the next-generation sequencing technologies. He was one of key members in developing and commercializing the next generation sequencing technologies at Lynx Therapeutics and Solexa, which was acquired by Illumina in late 2006. After the acquisition, he continued his tenure at Illumina and served as the Head of Sequencing Technologies for Illumina’s Asia Pacific Japan territory. He later joined Life Technologies as the Leader of Market Development. In this capacity, he teamed up with Professor Dennis Lo of the Chinese University of Hong Kong and contributed to developing the Non-invasive Prenatal Testing (NIPT).

Dr. Zhou received his B.Sc. in Biology from University of Science and Technology of China and Ph.D. in Medical Physiology from the University of Maryland at Baltimore. He completed his postdoctoral training at Duke University.